Mucosal delivery of nanovaccine strategy against COVID-19 and its variants

Lee, Junwoo; Khang, Dongwoo

doi:10.1016/j.apsb.2022.11.022

Cited by 3 publications

(3 citation statements)

References 230 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These candidates utilize different approaches. Interestingly, several candidates (Meissa Vaccines’ MV-014-212 and Codagenix’s COVI-VAC, specifically) are administered intranasally, potentially improving accessibility by eliminating the need for sterile needles and reducing manufacturing costs, targeting conferring mucosal immunity, and reducing some issues related to vaccine hesitancy ( 27 , 28 ). Additionally, although no phase III trial data are available for LAV candidates, some manufacturers have proactively sought to respond to the emergence of VOC.…”

Section: Whole-virus Vaccinesmentioning

confidence: 99%

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Whole-virus Vaccinesmentioning

confidence: 99%

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Current intramuscular COVID-19 vaccines struggle to induce respiratory mucosal immunity, highlighting the need for strategies to enhance local mucosal immunity post-intramuscular immunization. 22,76,77 Several approaches have entered clinical trials and have been approved for urgent use. However, some vaccines trigger antiviral immunity against the vector backbone, potentially hindering the effectiveness of repeated vaccinations.…”

Section: Discussionmentioning

confidence: 99%

“…Most vaccines are administered intramuscularly, and establishing mucosal immunity is crucial, especially because COVID-19 is primarily a respiratory disease. Current intramuscular COVID-19 vaccines struggle to induce respiratory mucosal immunity, highlighting the need for strategies to enhance local mucosal immunity post-intramuscular immunization. ,, Several approaches have entered clinical trials and have been approved for urgent use. However, some vaccines trigger antiviral immunity against the vector backbone, potentially hindering the effectiveness of repeated vaccinations. , Our data suggest that the EV-RBD vaccine is a safe and effective mucosal vaccine capable of inducing robust mucosal immunity.…”

Section: Discussionmentioning

confidence: 99%

Virus-Mimetic Extracellular-Vesicle Vaccine Boosts Systemic and Mucosal Immunity via Immune Recruitment

Li,

Xing,

Meng

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Mucosal vaccines can prevent viruses from infecting the respiratory mucosa, rather than only curtailing infection and protecting against the development of disease symptoms. The SARS-CoV-2 spike receptor-binding domain (RBD) is a compelling vaccine target but is undermined by suboptimal mucosal immunogenicity. Here, we report a SARS-CoV-2-mimetic extracellular-vesicle vaccine developed using genetic engineering and dendritic cell membrane budding. After mucosal immunization, the vaccine recruits antigen-presenting cells rapidly initiating a strong innate immune response. Notably, it obviates the need for adjuvants and can induce germinal center formation through both intramuscular and intratracheal vaccination. It not only elicits high levels of RBDspecific antibodies but also stimulates extensive cellular immunity in the respiratory mucosa. A sequential immunization strategy, starting with an intramuscular injection followed by an intratracheal booster, significantly bolsters mucosal immunity with high levels of IgA and tissue-resident memory T cell responses, thereby establishing a formidable defense against pseudovirus infection.

show abstract

Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants

Xi,

Ma,

et al. 2024

Vaccines

View full text Add to dashboard Cite

COVID-19, generated by SARS-CoV-2, has significantly affected healthcare systems worldwide. The epidemic has highlighted the urgent need for vaccine development. Besides the conventional vaccination models, which include live-attenuated, recombinant protein, and inactivated vaccines, nanovaccines present a distinct opportunity to progress vaccine research and offer convenient alternatives. This review highlights the many widely used nanoparticle vaccine vectors, outlines their benefits and drawbacks, and examines recent developments in nanoparticle vaccines to prevent SARS-CoV-2. It also offers a thorough overview of the many advantages of nanoparticle vaccines, including an enhanced host immune response, multivalent antigen delivery, and efficient drug delivery. The main objective is to provide a reference for the development of innovative antiviral vaccines.

show abstract

Mucosal delivery of nanovaccine strategy against COVID-19 and its variants

Cited by 3 publications

References 230 publications

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

Virus-Mimetic Extracellular-Vesicle Vaccine Boosts Systemic and Mucosal Immunity via Immune Recruitment

Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants

Contact Info

Product

Resources

About